## 4 Conclusions  
This study conducted an in-depth analysis of _Lentzea_ sp. JNUCC 0626, focusing on its taxonomic classification, complete genome sequencing, and biosynthetic gene cluster (BGC) mining. The findings highlight the strain's uniqueness and significant potential for biotechnological applications. The genome analysis revealed 34 BGCs, showcasing the strain's capacity to produce a diverse range of bioactive compounds, including terpenes, indolocarbazoles, nucleosides, peptides, polyketides, and peptide-polyketide hybrids. These discoveries position _Lentzea_ sp. JNUCC 0626 as a valuable genetic platform for the development of microbial factory systems, with promising implications for pharmacological and industrial applications. From a taxonomic perspective, _Lentzea jjuvenis_ JNUCC 0626 exhibits sufficient genetic differentiation from existing Lentzea species, supported by ANI (average nucleotide identity) and dDDH (digital DNA-DNA hybridization) analyses. This evidence strongly suggests that the strain could be considered a novel species. Furthermore, its isolation from the unique Jeju Gotjawal environment reflects its distinctive ecological origin and adaptive traits, underscoring its importance as a new taxonomic entity. Notably, the presence of plasmids in \(L\). _jejuensis_ JNUCC 0626 provides significant opportunities for the development of host-vector systems. These plasmids enable combinatorial biosynthesis, facilitating the efficient production of novel bioactive compounds and demonstrating the strain's potential as a critical tool in microbial factory technologies for drug discovery and other biotechnological applications. Moreover, this study experimentally confirmed the anti-inflammatory activity of \(L\). _jejuensis_ JNUCC 0626 extracts, providing direct evidence of the bioactivity of secondary metabolites predicted through genome analysis. This highlights the strain's potential as a valuable resource for natural product-based drug development. Additionally, _L. jejuniis_ JNUCC 0626 offers a promising platform for genetic engineering to enhance the production of specific compounds or the design of novel molecules. Its diverse BGCs make it an excellent candidate for combinatorial biosynthesis, enabling modifications of existing drugs or the synthesis of entirely new compounds. The identified BGCs also hold significant promise for addressing challenges such as antibiotic resistance and developing new anti-inflammatory agents. This research establishes _L. jejuniis_ JNUCC 0626 as a unique and promising biological and biotechnological resource, providing new possibilities for natural product-based drug development. Future studies on gene function characterization, metabolic pathway analysis, and the experimental validation of bioactive compounds will further enhance the strain's industrial and pharmacological potential. **Supplementary Materials:** The following supporting information can be downloaded at: [[https://www.mdpi.com/article/10.3390/amh70010008/s1](https://www.mdpi.com/article/10.3390/amh70010008/s1)]([https://www.mdpi.com/article/10.3390/amh70010008/s1](https://www.mdpi.com/article/10.3390/amh70010008/s1)). Table S1. Comparison of mycelium of _Lentzea_ sp. JNUCC 0626, _Lentzea caverne_ KCTC 39804, and _Lentzea pundingi_ KCTC 39694 on various actinomycte media; Table S2. Cellular fatty acid composition of strain JNUCC 0626; Table S3. Biochemical characteristics of _Lentzea_ sp. strain JNUCC 0626 analyzed using the API ZYM system; Table S4. De novo assembly annotation gene ontology (GO) of strain JNUCC 0626; Table S5. Pairwise comparisons of _Lentzea_ sp. strain JNUCC 0626 against selected type strain genomes; Table S6. Average nucleotide identity (ANI) values of _Lentzea_ sp. strain JNUCC 0626 compared to selected type strain genomes; Tables S7-S41. Genetic organization and BLASTP annotation of proteins in BGCs from _Lentzea_ sp. JNUCC 0626; Figure S1. Results of polar lipids analysis conducted by Korean Culture Center of Microorganisms (KCCM); Figures S2-S29.